Florida population

Vinay Mehindru, MD, MBA appointed to the board of directors of RetinalGenix Technologies Inc.


Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) — RetinaGenix™ Technologies, Inc. (OTCQB: RTGN) (“RetinalGenix” or the “Company”), today announced the appointment of Vinay Mehindru, MD, MBA to the board of directors of RetinalGenix Technologies, Inc.

Dr. Mehindru is a multi-talented senior executive with over 25 years of experience in healthcare. His leadership spans population health and financial performance management. He has led several physician performance improvement strategies and built stakeholder alliances with clinical and financial integration. He currently serves on the board of Sanovas, Inc., SteriView™ Technologies, Inc., Intubation Science™, Inc, SinuGeniX™, Inc., OtoGeniX™ Inc., PulmoGeniX™ Technologies, Inc. and GastroGeniX™, Inc.

Graduating from medical school at 21, Dr. Mehindru was one of the youngest graduates in his native India. At age 27, he was on the faculty of the Cleveland Clinic where he was a senior internal medicine resident and did research in gastroenterology. Vinay has a second residency from the University of Florida in Emergency Medicine.

Vinay joined a private group of emergency physicians on Florida’s east coast with 47 providers, 75 employees, and more than 100,000 annual visits. He has considerable experience in airway management; working in a level 2 trauma center for 10 years. For 16 years he has taught difficult airway management for cardiovascular care and pediatric advanced care.

At the University of Texas at Dallas, he earned an Executive MBA with Honors, earning the Beta Gamma Sigma award given only to the top 5% of business students in the world. Dr. Mehindru is the founder and CEO of Exemplary health, a fully integrated health plan for self-funded employers based on the principles of population health management. With AdventHealth he was Chief Medical Officer and President of the Physician Network of AdventHealth, Tampa Bay, a population health society. As president of AdventHealth’s Clinically Integrated Networks, Dr. Mehindru built a network of 1,000 physicians and established quality benchmarks and measures. It was successful in reducing the historical annual cost increase of their employee health plan. As a voting member of the Strategy and Growth Council of the AdventHealth West Florida Division, Dr. Mehindru oversaw strategic initiatives for this $1.5 billion revenue division.

Dr Mehindru said: “I am delighted to be part of the board of directors of RetinalGenix. This technology is designed to screen large populations at relatively lower cost and reduce the overall disease burden in the given population. It addresses the 3 components of the Triple Aim of Population Health Management from the Institute for Health Care Improvement (IHI): 1. Improve population health 2. Reduce cost per capita 3. Improve experience by improving access.

“We welcome Dr. Mehindru to the board of directors of RetinalGenix Technologies, Inc. His MBA, public health and medical health background should complement many RetinalGenix initiatives, including the company’s initiatives to improve population health management and the planned OTCQB upgrade to NASDAQ listing,” said RetinalGenix President and CEO Jerry Katzman, MD.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are identified by the use of the words “may”, “believe”, “anticipate”, “have intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, “project” and similar expressions intended to identify forward-looking statements and include statements regarding the appointment of Dr. Mehindru supporting the company’s initiatives to improve population health management and the planned upgrade of OTCBQB’s NASDAQ listing and the company’s technology screening large populations at cost relatively lower and reducing the overall disease burden in the given population. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results differ materially from current expectations. and assumptions from those set forth or implied by any forward-looking statement. Important factors that could cause actual results to differ materially from current expectations include, among others, Dr. Mehindru’s contribution to the Company, the ability of the Company’s technology to screen large populations at relatively low costs. lower and reduce the overall burden of disease in the particular population and risk factors described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise, except if required by law.

Contact:RetinalGenix Technologies, Inc.Jerry Katzman, CEO[email protected]www.retinalgenix.com

A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4641abf8-34d8-4897-8314-321686e36dee

main logo

Vinay Mehindru Joins Retinalgenix Board of Directors

Vinay Mehindru, MD, MBA

Source: RetinalGeniX Technologies, Inc.